PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) appointed biotechnology executive Joseph Truitt to its board as the company prepares to move two cell-therapy programs toward regulatory and clinical milestones in 2026.
Century expects to submit an investigational new drug application for CNTY-813, its induced pluripotent stem cell-derived islet replacement therapy for type 1 diabetes, in the fourth quarter.
The company said a pre-IND meeting with the U.S. Food and Drug Administration resulted in alignment on the program’s nonclinical data package, manufacturing strategy and proposed Phase 1/2 trial design.
Century also expects CNTY-308, a CD19-targeted CD4+/CD8+ αβ CAR-iT cell therapy for B-cell-mediated diseases, to enter clinical development this year.
Both candidates are engineered using Century’s Allo-Evasion 5.0 platform.
Truitt is chief executive officer and a director of iECURE Inc., a clinical-stage biotechnology company developing genome-editing therapies for rare genetic diseases. He is also chairman of Larimar Therapeutics (Nasdaq: LRMR) and a director of Code Biotherapeutics.
“Joe brings a rare combination of commercial leadership and global operational discipline to our board, having built and scaled multiple biotechnology organizations through periods of significant growth and transition,” Century Chief Executive Officer Brent Pfeiffenberger said.
Truitt previously led BioSpecifics Technologies Corp. until its acquisition by Endo International plc in December 2020.
Before BioSpecifics, he spent more than a decade at Achillion Pharmaceuticals, holding positions including chief commercial officer, chief operating officer and chief executive officer. Achillion was acquired by Alexion Pharmaceuticals in January 2020.
Truitt previously served as a captain in the U.S. Marine Corps. He holds an MBA from Saint Joseph’s University and a bachelor’s degree from La Salle University.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.